CompletedPhase 1ACTRN12605000523606

A Phase I Study to Determine the Pharmacokinetics of Nestorone Delivered with the Metered Dose Transdermal System (MDTS) in Postmenopausal Women, to be used in contraception


Sponsor

FemPharm Pty Ltd and/or Acrux DDS Pty Ltd

Enrollment

6 participants

Start Date

Aug 1, 2004

Study Type

Interventional

Conditions


Eligibility

Sex: FemalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This is an early-phase study looking at: A Phase I Study to Determine the Pharmacokinetics of Nestorone Delivered with the Metered Dose Transdermal System (MDTS) in Postmenopausal Women, to be used in contraception. It may be open to women aged 18 and older. Key requirements include: Healthy post-menopausal women Participation typically involves medical assessments and follow-up visits as part of the research.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Nestorone Metered Dose Transdermal System (MDTS), 6 days.

Nestorone Metered Dose Transdermal System (MDTS), 6 days.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000523606


Related Trials